Crossmark

Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study

Crossref DOI link: https://doi.org/10.1186/s12885-019-6122-2

Published Online: 2019-09-18

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mizushima, Tsunekazu https://orcid.org/0000-0002-0825-6823
Ikeda, Masataka

Kato, Takeshi

Ikeda, Atsuyo

Nishimura, Junichi

Hata, Taishi

Matsuda, Chu

Satoh, Taroh

Mori, Masaki

Doki, Yuichiro
Funding

Funding for this research was provided by:

Supporting Centre for Clinical Research and Education
License Information

Text and Data Mining valid from 2019-09-18

Version of Record valid from 2019-09-18
More Information

Article History

Received: 19 June 2019

Accepted: 2 September 2019

First Online: 18 September 2019

Ethics approval and consent to participate

: The Osaka University Clinical Research Review Committee approved this study (approval number: 12034). All patients provided written informed consent.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below